About SQZBiotech
SQZBiotech is a publicly listed company based in Boston (United States) founded in 2013, and was acquired by Stem Cell Technologies in February 2024. Cell therapies are developed using proprietary Cell Squeeze technology. SQZBiotech has raised $167.41 million across 16 funding rounds from investors including Boeing, Stem Cell Technologies and HHS. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
SQZBiotech was founded in 2013 and is based in Boston, United States. Operations focus on the biotechnology sector, where cell therapies are engineered to address oncology, autoimmune, and infectious diseases. Proprietary Cell Squeeze technology is employed to insert biological materials into diverse cell types, enabling therapeutic applications. A pipeline of treatments is maintained across these disease areas.
- Headquarters Boston, United States
- Stage Acquired
- SectorsHealthcare
- Website sqzbiotech.com
- Social LinkedIn X Facebook
- Acquired by Stem Cell Technologies (Feb 2024)
- Legal Name Sqz Biotechnologies Company
- Annual Revenue$21.48 M (USD)-20.74as on Dec 31, 2022
- Net Profit-$79.46 M (USD)-15.6as on Dec 31, 2022
- EBITDA-$64.14 M (USD)-11.09as on Dec 31, 2022
- Total Equity Funding$167.41M (USD)
in 16 rounds
- Latest Funding Round$2M (USD), Grant
Mar 2022
- InvestorsBoeing
& 21 more
- Acquired byStem Cell Technologies
(Feb 2024)
Funding Insights of SQZBiotech
SQZBiotech has successfully raised a total of $167.41M across 16 strategic funding rounds. The most recent funding activity was a Grant round of $2 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $167.41M
- Total Rounds 16
- Last Round Grant — $2M
- First Round $15,000
(Apr 2014)
- Investors Count 21
Latest 10 of 16 funding rounds of SQZBiotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $2M | Grant | – | – | |
| Mar 2022 | $448,672 | Grant | – | – | |
| May 2020 | $66.25M | Series D | – | Temasek | |
| Sep 2018 | $244,241 | Grant | – | – | |
| Aug 2018 | $72M | Series C | – | EverBlu Capital, Invus | |
| Dec 2017 | Series B | – | – | ||
| Dec 2016 | $24.06M | Series B | – | NanoDimension, Polaris Partners | – |
| Apr 2016 | $1.25M | Grant | – | – | |
| Aug 2015 | $1.45M | Grant | – | – | |
| Jul 2015 | $5.08M | Series A | – | Polaris Partners |
22 investors in total: 22 institutional.
Investors in SQZBiotech
SQZBiotech has secured backing from 22 investors, including institutional and venture fund investors. Prominent investors backing the company include Boeing, Stem Cell Technologies and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Health tech startups are invested in by Illumina Ventures. | illuminaventures.com | Foster City, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Global health technologies are catalyzed by this nonprofit organization. | ghif.com | |||
US focused VC firm | nanodimension.com | Woodside, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
| vivaventuresbiotech.com | ||||
Companies developing T1D products are funded through venture philanthropy. | t1dfund.org | Boston, United States | ||
Tech & Life Sciences focused early stage VC firm investing in North America | quarkventure.com | Vancouver, Canada | ||
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States |
Investor details for SQZBiotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SQZBiotech
19 people are tracked at SQZBiotech (3 in leadership, 12 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Kathleen Large | VP, Clinical Operations | Leadership |
Richard Capasso | Chief Accounting Officer | Leadership |
Mandy Duvall | Head Of Clinical Development Strategic Planning & Management | Leadership |
Darrell Irvine | Advisor | Board & advisors |
Sapna Srivastava | Director | Board & advisors |
Paul Bolno | Director | Board & advisors |
Klavs Jensen | Director | Board & advisors |
Amy Schulman | Director | Board & advisors |
Marc Elia | Director | Board & advisors |
Pushkal Garg | Director | Board & advisors |
David Sachs | Director | Board & advisors |
Mark Shlomchik | Advisor | Board & advisors |
Kai Wucherpfennig | Advisor | Board & advisors |
Tyler Jacks | Advisor | Board & advisors |
Arlene Sharpe | Advisor | Board & advisors |
Larry Knopf | General Counsel | Team |
Waleed Khan | Laboratory Technician | Team |
Rachel P. | Research Associate | Team |
Bing Xie | Human Resources Manager | Team |
Complete people profiles for SQZBiotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of SQZBiotech
SQZBiotech is a publicly listed company on the OTC with ticker symbol SQZB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Oct 2020
- Listed onNYSE: SQZ
- Listed entitySQZ Biotechnologies Company
- Exchange sectorHealth technology
- ISINUS78472W1045
- Share price$0.02 · 2026-10-12
- Market capitalisation$707,787.00
- Volume (last session)148
Financials of SQZBiotech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $21.5M | -$79.5M | -$64.1M |
| 2021 | $27.1M | -$68.7M | -$57.7M |
| 2020 | $21.0M | -$50.5M | -$40.1M |
Detailed financial statements for SQZBiotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of SQZBiotech
5 dated milestones of SQZBiotech across 11 years, from founding to its latest funding, stage changes and deals.
- Founded SQZBiotech is founded.
- Funding First funding round of $15K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $2.0M.
- Exit Acquired by Stem Cell Technologies.
Competitors of SQZBiotech
SQZBiotech has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of SQZBiotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as SQZBiotech (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sqzbiotech
Complete news archive for SQZBiotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SQZBiotech
SQZBiotech was founded in 2013 and raised its 1st funding round 1 year after it was founded.
SQZBiotech is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
SQZBiotech is a funded company, having raised a total of $167.41M across 16 funding rounds to date. The company's 1st funding round was a Series A of $5.08M, raised on Apr 2014.
Annual revenue of SQZBiotech is $21.48M as on Dec 31, 2022.
SQZBiotech was founded in 2013 and is based in Boston, United States. Operations focus on the biotechnology sector, where cell therapies are engineered to address oncology, autoimmune, and infectious diseases. Proprietary Cell Squeeze technology is employed to insert biological materials into diverse cell types, enabling therapeutic applications. A pipeline of treatments is maintained across these disease areas.
SQZBiotech's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Yes, SQZBiotech is publicly traded on OTC under the ticker symbol SQZB.
SQZBiotech has 22 investors. Key investors include Boeing, Stem Cell Technologies, HHS, Temasek, and National Institute of General Medical Sciences.
Yes. SQZBiotech was acquired by Stem Cell Technologies in February 2024.